加载中
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$5.08
−US$0.195 · -3.70%
常规交易时段
US$5.08
−US$0.195 · -3.70%
盘中时间采用ET。市场数据可能有所延迟。
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
日内区间
当前US$5.08
52周区间
当前US$5.08
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 1.07万 USD | — | 1.19万 USD | — | — |
| 毛利 | −1.07万 USD | — | −1.19万 USD | — | — |
| 研究与开发 | 2.83万 USD | 88.02万 USD | 4.5万 USD | 161.95万 USD | 173.46万 USD |
| 销售、一般及管理费用 | 5.51万 USD | 126.18万 USD | 4.31万 USD | 62.48万 USD | 4.45万 USD |
| 营业费用 | 8.34万 USD | 254.16万 USD | 8.81万 USD | 237.44万 USD | 183.69万 USD |
| 利息收入 | 776.16 USD | 5.35万 USD | 2.14万 USD | 243 USD | 28 USD |
| 折旧和摊销 | 1.07万 USD | 39.96万 USD | 36.52万 USD | 12.66万 USD | 5.79万 USD |
| 营业利润 | −9.41万 USD | −254.16万 USD | −10万 USD | −237.44万 USD | −183.69万 USD |
| 净利润 | −10.15万 USD | −278.23万 USD | −12.15万 USD | −402.77万 USD | −183.72万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年2月20日 | 1:20 | — | — |
已生效 2026年2月20日
1:20
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
